Servier, a Paris, France-based independent international pharmaceutical company, completed the acquisition of Symphogen A/S.
The amount of the deal was not disclosed.
Symphogen will now function as Servier’s antibody center of excellence across multiple therapeutic areas, including oncology. Symphogen, now a Servier subsidiary, will keep its operational autonomy and continue to have its experienced employees while maintaining its headquarters in Ballerup, Denmark.
As part of the acquisition, Christophe Thurieau, Executive Director of Servier Research Institute, has been appointed Chief Executive Officer of Symphogen and Karin Garre, former Chief Operating Officer of Symphogen, has been appointed General Manager of Symphogen. Martin Olin, former Chief Executive Officer of Symphogen, will act as an external consultant to support this transition.